Product Information |
Product name |
Ritonavir |
CAS No. |
155213-67-5 |
Molecular Formula |
C37H48N6O5S2 |
Molecular Weight |
720.96 |
Quality Standard |
99% up, USP42, Medicine Grade |
Appearance |
White powder |
COA of Ritonavir |
Items |
Specifications |
Results |
Appearance |
White to off-white powder |
White powder |
Solubility |
Freely solution in methanol and in ethanol, soluble in 2-propanol |
Conforms |
Identification |
HPLC: the retention time of the test sample corresponds to that of the reference standard
IR: the infrared absorption spectrum of the test sample is concordant with the spectrum of reference standard |
Conforms
Conforms |
Water content by KF |
NMT 0.5% |
0.06% |
Specific optical rotation |
+7.0°~+10.5°(c=2 in MeOH) |
+10.21° |
Residue on ignition |
NMT 0.2% |
0.10% |
Heavy metals |
NMT 20 ppm |
Conforms |
Sulphated ash |
NMT 0.105 |
0.03% |
Organic volatile impurities |
Ethylacetate: NMT 0.5% Heptane: NMT 0.5% Tetrahydrofuran: NMT 0.072% |
0.40% 0.16% ND |
Related substances (by HPLC, area%) |
Impurity E (RRT=0.36):NMT 0.3% ImpurityO(RRT=1.11):NMT 0.3% Impurity T (RRT=2.87):NMT 0.2% Any other individual impurity: NMT 0.1% Total impourities: NMT1.0% |
0.08% ND ND Conforms 0.16% |
Assay (by HPLC) |
98.0%~102.0% |
99.0% |
Usage |
Function of Ritonavir
What is Ritonavir ?
Ritonavir is a Whtie
powder, It's CAS No. is 155213-67-5, It's molecular formula is C37H48N6O5S2.
Ritonavir, with trade name Norvir
(AbbVie, Inc.), is an antiretroviral drug from the protease inhibitor class
used to treat HIV infection and AIDS.
Function of Ritonavir
Ritonavir is an HIV
protease inhibitor that interferes with the reproductive cycle of HIV.
It is now more commonly used as a
booster of other protease inhibitors and is available in both liquid
formulation and as capsules.
Application of Ritonavir
1. Ritonavir is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS.
2.
Ritonavir is a Pharmaceutical raw materials.
3. Although it was initially
developed as an independent agent, it has been shown to possess advantageous
properties in combination
regimens with low-dose ritonavir and other protease inhibitors.
*Products under the patent are only for R&D use